基于稳定同位素标记的蛋白质组学定量方法研究进展

定量蛋白质组学已经成为后基因时代的重要研究方向之一。目前该领域的研究主要采用无标记定量方法和稳定同位素标记定量法。其中,基于稳定同位素标记的蛋白质组定量方法发展非常迅速,已为生命科学研究提供了重要的技术支撑。本文分析了基于稳定同位素标记的蛋白质组学定量方法,包括相对定量方法和绝对定量方法,并对其发展进行了展望。     

基于生物质谱的乙酸酐稳定同位素标记定量蛋白质组学方法的建立与优化

建立了一种基于生物质谱的乙酸酐稳定同位素标记,定量蛋白质组学研究方法,优化了影响标记效率的各种条件。在pH8.0的Na2B4O7/H3BO3缓冲体系中,当乙酸酐摩尔浓度25倍过量于肽段摩尔量,22℃反应30 min时,标记即可完全。对多对H6/D6-乙酸酐标记肽段在基质辅助激光解吸电离质谱中的动态范围及定量准确度进行了考察,并通过串联质谱分析确定了乙酰化位点。结果表明:在10倍和30倍动态范围内,线性关系良好(r=0.99,r=0.98),理论值和观测值的偏差分别为0.5%和20%。     

基于生物质谱的乙酸酐稳定同位素标记

建立了一种基于生物质谱的乙酸酐稳定同位素标记,定量蛋白质组学研究方法,优化了影响标记效率的各种条件.在pH 8.0的Na2B4O7/H3BO3 缓冲体系中,当乙酸酐摩尔浓度25倍过量于肽段摩尔量,22℃反应30 min时,标记即可完全.对多对H6/D6-乙酸酐标记肽段在基质辅助激光解吸电离质谱中的动态范围及定量准确度进行了考察,并通过串联质谱分析确定了乙酰化位点.结果表明: 在10倍和30倍动态范围内,线性关系良好(r=0.99, r=0.98),理论值和观测值的偏差分别为0.5%和20%.     

比较蛋白质组学研究中的稳定同位素标记技术

比较蛋白质组学是指在蛋白质组学水平上研究正常和病理情况下细胞或组织中蛋白质表达变化,以期发现具有重要功能的生物标识物,为疾病的早期诊断提供依据。近年来它正成为蛋白质组学研究的热点和发展趋势。比较蛋白质组学的研究方法和策略有多种,本文就最近几年来稳定同位素标记技术(体内代谢标记技术和体外化学标记技术)在比较蛋白质组学研究中的进展进行综述。     

18O稳定同位素标记定量蛋白质组研究技术的建立与优化

建立了18O稳定同位素标记方法,用于复杂体系蛋白质相对定量分析。对影响蛋白质标记稳定性的实验条件进行了比较和优化。结果表明,采用酶切后标记的方法,酶切肽段在胰酶催化下,在pH 5.0的K2HPO4/KH2PO4缓冲体系中,37℃18O标记反应16 h,绝大部分肽段即可达到100%的标记效率。对多个16O/18O成对肽段峰强度的动态范围及定量准确度进行了考察。结果表明,18O标记方法是一种简便、稳定、可靠的相对定量方法,10倍动态范围内,标记率相对标准偏差在18.4%以内,16O/18O峰强度呈很好的线性关系。本实验考察了标记后的肽段在不同溶液体系中的稳定性,为复杂样品的预处理和预分离的溶液条件提供了依据。     

基于稳定同位素标记与质谱分析的蛋白质定量算法研究进展

蛋白质定量研究已成为蛋白质组学的热点,它是疾病相关生物标志物发现的重要途径.基于稳定同位素标记的质谱分析技术是蛋白质定量最常用的方法之一.随着实验方法的发展和改进,定量数据处理方法也在不断更新与完善.一般来说,定量数据处理包括四步:搜库鉴定、图谱定量信息提取与计算、肽段丰度比计算和蛋白质丰度比计算及差异显著性分析,其中后三步是数据处理的核心.目前,后三步中每步都有多种可选算法,这些算法一般都是针对特定实验技术而提出的,缺乏深入的工作对它们进行系统比较和优化.为此,在总结目前主要实验技术方法的基础上,论述了定量算法的现状和存在问题,并针对一些问题提出了可行的解决办法.     

18O同位素标记定量肽段串联体蛋白质结合同位素稀释-多反应监测质谱的蛋白质绝对定量新方法

建立了定量肽段串联体蛋白质(concatamers of Q peptides, QconCATs)结合¹⁸O同位素标记-多反应监测质谱的蛋白质绝对定量新方法。首先对QconCAT重组蛋白质进行了纯度表征,十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)表征结果表明重组蛋白质的纯度在99%以上,相对分子质量约为63.4 kDa。对QconCAT重组蛋白质酶切后的肽段混合物进行质谱分析,并经pFind和pLabel软件处理,验证了目标肽段。还考察了QconCAT重组蛋白质的酶切效率和¹⁸O标记效率,并对QconCAT蛋白质结合¹⁸O标记-同位素稀释-多反应监测质谱方法进行了评价。实验结果表明,采用该方法对腾冲嗜热厌氧菌(Thermoanaerobacter tengcongensis, TTE)中选定蛋白质的肽段进行绝对含量测定时,相对标准偏差小于20%,准确度较高,说明该方法可用于复杂生物样本中蛋白质的绝对定量。更重要的是所建方法不仅解决了细胞培养氨基酸稳定同位素标记(SILAC)技术的重标试剂价格昂贵的问题,也为定量蛋白质组学提供了一种新的方法。     

定量蛋白质组学质谱采集技术进展

质谱是定量蛋白组学的主要工具。近年来随着定量蛋白质组学研究的深入,传统质谱定量技术面临着复杂基质干扰、分析通量限制等诸多问题。而最近一系列质谱新技术的发展,包括同步母离子选择( SPS)、质量亏损标记、平行反应监测(PRM)、多重累积(MSX)和多种全新数据非依赖性采集(DIA)等,为解决目前蛋白质组学在相对定量和绝对定量分析方面的局限提供了有效途径。本文对定量蛋白质组学目前遇到的瓶颈问题进行了分析,总结了质谱定量采集技术的最新进展,并评述了这些新技术的特点以及在定量蛋白质组学应用中的优势。     

小硅藻光合作用脂13 C稳定同位素定量标记分析

以小硅藻( Nitzschia closterium f. minutissima)作为研究对象,利用超高压液相色谱联用四极杆-静电场轨道阱高分辨质谱技术,研究了处于平台期的小硅藻中的光合作用脂被13 C标记的程度和速度。结果显示：在平台期13 C人工标记的10天内,所有4类光合作用脂均被13 C明显标记,其中二酰甘油双半乳糖脂( DG-DG)、磷脂酰甘油( PG)、二酰甘油硫代糖脂( SQDG)被13 C标记的总量,从刚进入平台期到平台期第8天逐渐增加,此后出现下降趋势,在第8天分别达到最大值(173±24) ng/mg,(473±41) ng/mg 及(1224±21) ng/mg,标记率分别达到56.3%,38.4%和62.6%;而二酰甘油单半乳糖脂(MGDG)被13C标记的总量在整个平台期呈现持续上升趋势,并在第10天达到(956±51) ng/mg,标记率为87.3%。可见,不同脂质在藻体内合成的先后时间有差别,为了清晰地了解生物摄食过程中对微藻中特定脂类的同化机理,需要藻体内被13 C标记的每类脂质含量的最大化,针对DGDG、PG、SQDG,应选取标记了8天的微藻来投喂生物,而针对MGDG,则应选取标记了10天的微藻投喂生物。     

核酸工具酶辅助的金属稳定同位素标记方法在生物分析中的应用

本文主要概述了近年来核酸工具酶辅助的基于金属稳定同位素标记的电感耦合等离子体质谱(ICP-MS)检测方法在生物分析中的发展和应用,简要介绍了该方法在蛋白质、核酸及一些生物小分子检测中的应用。最后对核酸工具酶辅助的基于金属稳定同位素标记的电感耦合等离子体质谱(ICP-MS)检测方法的发展前景做了展望。     

等电聚焦预分离用于肝癌细胞分泌蛋白质组的分级与鉴定

分泌蛋白质组(secretome)是指在特定的时空条件下,细胞、组织等分泌的全部蛋白质。分泌蛋白质组可能包含了大量的疾病诊断生物标志物,因此其相关研究越来越受到重视。分泌蛋白质组的组成高度复杂且浓度范围宽,这对分析方法提出了挑战。建立有效的蛋白质或肽段预分离策略,将有利于分泌蛋白质的高覆盖率鉴定。本研究以肝癌细胞系MHCC97L的无血清培养分泌蛋白质为研究对象,采用一种新型等电聚焦预分离(OFFGEL)系统,考察了肽段水平的分级对蛋白质鉴定结果的影响。结果表明,分离后各馏分中肽段的等电点分布与理论预测基本一致,每个馏分中单独鉴定的肽段比例接近80%,显示了该系统对肽段的高分辨分离能力。结合生物质谱技术,在肝癌细胞分泌系统中鉴定了2995个蛋白质,显示了该系统在复杂体系蛋白质组研究中的应用潜力。     

Thiol-reactive dyes for fluorescence labeling of proteomic samples

Covalent derivatization of proteins with fluorescent dyes prior to separation is increasingly used in proteomic research. This paper examines the properties of several commercially available iodoacetamide and maleimide dyes and discusses the conditions and caveats for their use in labeling of proteomic samples. The iodoacetamide dyes BODIPY TMR cadaverine IA and BODIPY Fl C(1)-IA were highly specific for cysteine residues and showed little or no nonspecific labeling even at very high dye:thiol ratios. These dyes also showed minimal effects on pI's of standard proteins. Some iodoacetamide dyes, (5-TMRIA and eosin-5-iodoacetamide) and some maleimide dyes (ThioGlo I and Rhodamine Red C(2) maleimide) exhibited nonspecific labeling at high dye:thiol ratios. Labeling by both iodoacetamide and maleimide dyes was inhibited by tris(2-carboxyethyl)phosphine (TCEP); interactions between TCEP and dye were also observed. Thiourea, an important component of sample solubilization cocktails, inhibited labeling of proteins with iodoacetamide dyes but not with maleimide dyes. Maleimide dyes may serve as an alternative for labeling proteins where it is essential to have thiourea in the solubilization buffer. Covalent derivatization by BODIPY TMR cadaverine IA, BODIPY Fl C(1)-IA or Rhodamine Red C(2) maleimide was also demonstrated to be compatible with in-gel digestion and peptide mass fingerprinting by matrix assisted laser desorption/ionization-mass spectrometry and allowed successful protein identification.     

Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM)

The need for a reliable and accurate method to quantify dystrophin proteins in human skeletal muscle biopsies has become crucial in order to assess the efficacy of dystrophin replacement therapies in Duchenne muscular dystrophy as well as to gain insight into the relationship between dystrophin levels and disease severity in Becker's muscular dystrophy. Current methods to measure dystrophin such as western blot and immunofluorescence, while straightforward and simple, lack precision and sometimes specificity. Here, we standardized a targeted mass spectrometry method to determine the absolute amount of dystrophin in ng/mg of muscle using full‐length ¹³C6–Arg– and ¹³C6,¹⁵N2–Lys–labeled dystrophin and parallel reaction monitoring (PRM). The method was found to be reproducible with a limit of quantification as low as 30 pg of dystrophin protein per mg of total muscle proteins. The method was then tested to measure levels of dystrophin in muscle biopsies from a healthy donor and from Duchenne and Becker's muscular dystrophy patients.     

Investigation on the viscoelasticity of synchronous hepatocellular carcinoma cells

Having made use of the micropipette aspiration technique, we here investigated the viscoelastic properties of hepatocellular carcinoma (HTC) cells from the view of cell cycle. The synchronous G₁ and S phase cells were achieved through thymine-2-desoryriboside and colchicine sequential blockage method and double thymine-2-desoryriboside blockage method, respectively. The synchronization results detected with flow cytometer showed that it could meet the requirements of the experiments nicely. Experimental results were analyzed with a standard linear solid viscoelastic model, in which an elastic element, K₁, is in parallel with a Maxwell element composed of another elastic element, K₂, in series with a viscous element, μ. The results indicated that high K₁, K₂ values and low μ value was the general characteristics of the cells; G₁ phase cells had higher K₁ values and low μ value than S phase cells, which endowed G₁ phase cells with higher elasticity and faster passive deformability than S phase cells. The results maybe also reflected the difference of cytoskeleton between G₁ and S phase cells, and suggested that G₁ phase cells were more suitable for surviving and metastasis in blood circulation than S phase cells.     

集成化蛋白质组定量分析平台的构建及应用

为提高蛋白质组定量分析的准确度、通量和自动化程度,构建了由微升级混合离子交换色谱、亲水型固定化酶反应器（hIMER）和纳升级反相色谱-电喷雾串级质谱（nanoRPLC-ESI-MS/MS）组成的集成化蛋白质定量分析平台。该平台实现了二甲基化标记蛋白质样品在线分离、酶解、肽段分离鉴定和定量分析。采用质量比为1：1的轻、重标记的蛋白质样品考察该平台的定量性能,发现蛋白质水平二甲基化标记效率为90%;蛋白质经hIMER在线酶解10 min产生的漏切及酶解产物在hIMER柱上的非特异性吸附对定量准确度的影响较小,所有定量到的重/轻标记的蛋白质质量比的平均值为1.01。最后将该平台应用于小鼠腹水型肝癌淋巴道高、低转移细胞系差异蛋白质的分析,发现了12种蛋白质在高转移细胞系中低表达,15种蛋白质在高转移细胞系中高表达。以上结果证明了该平台可以实现高准确度和高通量的蛋白质组定量分析。     

Dansylation isotope labeling liquid chromatography mass spectrometry for parallel profiling of human urinary and fecal submetabolomes

Human urine and feces can be non-invasively collected for metabolomics-based disease biomarker discovery research. Because urinary and fecal metabolomes are thought to be different, analysis of both biospecimens may generate a more comprehensive metabolomic profile that can be better related to the health state of an individual. Herein we describe a method of using differential chemical isotope labeling (CIL) liquid chromatography mass spectrometry (LC-MS) for parallel metabolomic profiling of urine and feces. Dansylation labeling was used to quantify the amine/phenol submetabolome changes among different samples based on ¹²C-labeling of individual samples and ¹³C-labeling of a pooled urine or pooled feces and subsequent analysis of the ¹³C-/¹²C-labeled mixture by LC-MS. The pooled urine and pooled feces are further differentially labeled, mixed and then analyzed by LC-MS in order to relate the metabolite concentrations of the common metabolites found in both biospecimens. This method offers a means of direct comparison of urinary and fecal submetabolomes. We evaluated the analytical performance and demonstrated the utility of this method in the analysis of urine and feces collected daily from three healthy individuals for 7 days. On average, 2534 ± 113 (n = 126) peak pairs or metabolites could be detected from a urine sample, while 2507 ± 77 (n = 63) peak pairs were detected from a fecal sample. In total, 5372 unique peak pairs were detected from all the samples combined; 3089 and 3012 pairs were found in urine and feces, respectively. These results reveal that the urine and fecal metabolomes are very different, thereby justifying the consideration of using both biospecimens to increase the probability of finding specific biomarkers of diseases. Furthermore, the CIL LC-MS method described can be used to perform parallel quantitative analysis of urine and feces, resulting in more complete coverage of the human metabolome.